{"id":"NCT05395091","sponsor":"Alvotech Swiss AG","briefTitle":"Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND","officialTitle":"A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopausal Women With Osteoporosis, ALVOBOND","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-23","primaryCompletion":"2024-05-07","completion":"2024-10-28","firstPosted":"2022-05-27","resultsPosted":"2025-05-29","lastUpdate":"2025-05-29"},"enrollment":532,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis, Postmenopausal"],"interventions":[{"type":"BIOLOGICAL","name":"AVT03","otherNames":[]},{"type":"BIOLOGICAL","name":"Denosumab","otherNames":["Prolia"]}],"arms":[{"label":"AVT03","type":"EXPERIMENTAL"},{"label":"Prolia","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.","timeFrame":"Baseline to Month 12","effectByArm":[{"arm":"AVT03","deltaMin":5.3,"sd":0.87},{"arm":"Prolia","deltaMin":5.18,"sd":0.872}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":34,"countries":["Bulgaria","Czechia","Georgia","Poland","South Africa"]},"refs":{"pmids":["40698538"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":266},"commonTop":["Upper respiratory tract infection","Hypocalcaemia","Nasopharyngitis","Activated partial thromboplastin time prolonged","Adjusted calcium decreased"]}}